Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations

References

• SiegelRL , MillerKD , JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• NakamuraT , NawaK , IchiharaA. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun.122(3), 1450–1459 (1984).
   PubMed Web of Science ®Google Scholar
• SchmidtL , DuhFM , ChenFet al.Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet.16(1), 68–73 (1997).
   PubMed Web of Science ®Google Scholar
• DiRenzo MF , OliveroM , MartoneTet al.Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene19(12), 1547–1555 (2000).
   PubMed Web of Science ®Google Scholar
• GhadjarP , Blank-LissW , SimcockMet al.MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin. Exp. Metastasis26(7), 809–815 (2009).
   PubMed Web of Science ®Google Scholar
• deMelo Gagliato D , JardimDLF , FalchookGet al.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson phase I unit. Clin. Breast Cancer14(6), 468–474 (2014).
   PubMed Web of Science ®Google Scholar
• NeklasonDW , DoneMW , SargentNRet al.Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer11, 424 (2011).
   PubMed Web of Science ®Google Scholar
• SeiwertTY , JagadeeswaranR , FaoroLet al.The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res.69(7), 3021–3031 (2009).
   PubMed Web of Science ®Google Scholar
• MaPC , JagadeeswaranR , JagadeeshSet al.Functional expression and mutations of c-MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res.65(4), 1479–1488 (2005).
   PubMed Web of Science ®Google Scholar
• MaPC , KijimaT , MaulikGet al.c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res.63(19), 6272–6281 (2003).
   PubMed Web of Science ®Google Scholar
• SattlerM , SalgiaR. MET in the driver's seat: exon 14 skipping mutations as actionable targets in lung cancer. J. Thorac. Oncol.11(9), 1381–1383 (2016).
   PubMed Web of Science ®Google Scholar
• MaulikG , KijimaT , MaPCet al.Modulation of the c-MET/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res.8(2), 620–627 (2002).
   PubMed Web of Science ®Google Scholar
• PaikPK , DrilonA , FanP-Det al.Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov.5(8), 842–849 (2015).
   PubMed Web of Science ®Google Scholar
• WolfJ , SetoT , HanJ-Yet al.Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. J. Clin. Oncol.37(Suppl. 15), 9004–9004 (2019).
   Google Scholar
• PaikPK , FelipE , VeillonRet al.Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. 383(10), 931–943 (2020).
   Google Scholar
• CappuzzoF , JannePA , SkokanMet al.MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol.20(2), 298–304 (2009).
   PubMed Web of Science ®Google Scholar
• MartinV , ChiriacoC , ModicaCet al.MET inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br. J. Cancer120(5), 527–536 (2019).
   PubMed Web of Science ®Google Scholar
• ReisPP , WaldronL , GoswamiRSet al.mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol.11, 46 (2011).
   PubMed Web of Science ®Google Scholar
• WangH , HorbinskiC , WuHet al.NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. Nucleic Acids Res.44(20), e151 (2016).
   PubMed Web of Science ®Google Scholar
• TitmarshHF , O'ConnorR , DhaliwalK , AkramAR. The emerging role of the c-MET-HGF axis in non-small lung cancer tumor immunology and immunotherapy. Front. Oncol.10, 54 (2020).
   PubMed Web of Science ®Google Scholar
• AhnHK , KimS , KwonDet al.MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function. Int. J. Mol. Sci.20(17), 4287 (2019).
   PubMed Web of Science ®Google Scholar
• GeissGK , BumgarnerRE , BirdittBet al.Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol.26(3), 317–325 (2008).
   PubMed Web of Science ®Google Scholar
• MaPC , TretiakovaMS , MacKinnonACet al.Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer47(12), 1025–1037 (2008).
   PubMed Web of Science ®Google Scholar
• EngelmanJA , ZejnullahuK , MitsudomiTet al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• RaghavK , MorrisV , TangCet al.MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget7(34), 54627–54631 (2016).
   PubMedGoogle Scholar
• TanYH , KrishnaswamyS , NandiSet al.CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS ONE5(1), e8972 (2010).
   PubMed Web of Science ®Google Scholar
• GuoR , LuoJ , ChangJ , RekhtmanN , ArcilaM , DrilonA. MET-dependent solid tumours–molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol.17(9), 569–587 (2020).
   PubMed Web of Science ®Google Scholar
• SalgiaR , SattlerM , ScheeleJ , StrohC , FelipE. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat. Rev.87, 102022 (2020).
   PubMed Web of Science ®Google Scholar
• YenBL , YenML , HsuPJet al.Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-MET and STAT3. Stem Cell Reports1(2), 139–151 (2013).
   PubMed Web of Science ®Google Scholar
• EternoV , ZambelliA , PavesiLet al.Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-MET signaling. Oncotarget5(3), 613–633 (2014).
   PubMedGoogle Scholar
• SaigiM , Alburquerque-BejarJJ , McLeer-Florin Aet al.MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin. Cancer Res.24(18), 4579–4587 (2018).
   PubMed Web of Science ®Google Scholar
• AlbitarM , SudarsanamS , MaWet al.Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget9(17), 13682–13693 (2018).
   PubMedGoogle Scholar
• DemuthC , AndersenMN , JakobsenKR , MadsenAT , SørensenBS. Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. Oncotarget8(40), 68221–68229 (2017).
   PubMedGoogle Scholar
• BlankC , BrownI , PetersonACet al.PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res.64(3), 1140–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-DiazA , ShinDS , MorenoBHet al.Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep.19(6), 1189–1201 (2017).
   PubMed Web of Science ®Google Scholar
• XingX , GuoJ , DingGet al.Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology7(3), e1356144 (2018).
   PubMed Web of Science ®Google Scholar
• SabariJK , LeonardiGC , ShuCAet al.PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann. Oncol.29(10), 2085–2091 (2018).
   PubMed Web of Science ®Google Scholar
• GloddeN , BaldT , vanden Boorn-Konijnenberg Det al.Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity47(4), 789–802.e789 (2017).
   PubMed Web of Science ®Google Scholar
• KumaiT , MatsudaY , OhkuriTet al.c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology4(2), e976077 (2015).
   PubMed Web of Science ®Google Scholar
• SpaethE , KloppA , DembinskiJ , AndreeffM , MariniF. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther.15(10), 730–738 (2008).
   PubMed Web of Science ®Google Scholar
• SonBR , Marquez-CurtisLA , KuciaMet al.Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-MET axes and involves matrix metalloproteinases. Stem Cells24(5), 1254–1264 (2006).
   PubMed Web of Science ®Google Scholar
• SimpsonAJ , CaballeroOL , JungbluthA , ChenYT , OldLJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer5(8), 615–625 (2005).
   PubMed Web of Science ®Google Scholar
• ChomezP , DeBacker O , BertrandM , DePlaen E , BoonT , LucasS. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res.61(14), 5544–5551 (2001).
   PubMed Web of Science ®Google Scholar
• NohST , LeeHS , LimSJet al.MAGE-A1-6 expression in patients with head and neck squamous cell carcinoma: impact on clinical patterns and oncologic outcomes. Int. J. Clin. Oncol.21(5), 875–882 (2016).
   PubMed Web of Science ®Google Scholar
• YiE , ChangJE , LeemC , JeonCH , JheonS. Association of MAGE A1-6 expression with lung cancer progression. J. Cancer8(8), 1324–1329 (2017).
   PubMed Web of Science ®Google Scholar
• MecklenburgI , SienelW , SchmidS , PasslickB , KuferP. A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung cancer. Clin. Cancer Res.23(5), 1213–1219 (2017).
   PubMed Web of Science ®Google Scholar
• MaoY , FanW , HuHet al.MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J. Hematol. Oncol.12(1), 106 (2019).
   PubMed Web of Science ®Google Scholar
• ThayaparanT , PetrovicRM , AchkovaDYet al.CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology6(12), e1363137–e1363137 (2017).
   PubMed Web of Science ®Google Scholar
• MojicM , TakedaK , HayakawaY. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int. J. Mol. Sci.19(1), 89 (2017).
   PubMed Web of Science ®Google Scholar
• TchouJ , ZhaoY , LevineBLet al.Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol. Res.5(12), 1152–1161 (2017).
   PubMed Web of Science ®Google Scholar
• LiuB , LiuZZ , ZhouMLet al.Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol. Med. Rep.20(3), 2823–2831 (2019).
   PubMed Web of Science ®Google Scholar